Key Points
-
A predisposition to renal cancer has been identified in several autosomal-dominant inherited cancer syndromes.
-
von Hippel–Lindau (VHL) disease, associated with conventional (clear-cell) renal-cell carcinomas and multi-organ neoplasia, is caused by germline mutations in the VHL tumour-suppressor gene and loss of the wild-type VHL allele.
-
Patients with hereditary papillary renal carcinoma (HPRC) harbour germline-activating mutations in the MET proto-oncogene, which can cause renal cancers with papillary type-1 histology.
-
Papillary type-2 renal carcinomas and cutaneous and uterine smooth-muscle tumours are associated with the syndrome of hereditary leiomyomatosis and renal-cell cancer (HLRCC), which is caused by germline loss-of-function mutations in the fumarate-hydratase (FH) gene.
-
The Birt–Hogg–Dubé syndrome (BHD) predisposes to cutaneous nodules (benign tumours of the hair follicle), spontaneous pneumothorax and an increased risk for renal cancers of various histological types, such as chromophobe renal-cell carcinoma and oncocytic hybrid renal tumour. BHD is caused by germline mutations in a newly discovered tumour-suppressor gene, BHD.
-
Hyperparathyroidism-jaw tumour syndrome (HPT-JT) is associated with parathyroid adenomas, fibro-osseous tumours of the jaw, and unusual renal tumours containing a mixture of epithelial and stromal elements. This syndrome is caused by germline mutations in HRPT2.
-
The identification of non-VHL families affected with clear-cell renal carcinomas, termed familial clear-cell renal carcinoma (FCRC), indicates that additional renal-cancer-predisposing genes remain to be identified.
-
Diagnosis and appropriate treatment of these hereditary renal-cancer-associated syndromes relies on an understanding of their clinical spectrum, accurate histological evaluation of renal tumours from patients and on genetic testing for predisposing genes.
Abstract
Families with hereditary predispositions to cancer continue to provide a unique opportunity for the identification and characterization of genes involved in carcinogenesis. A surprising number of genetic syndromes predispose to the development of renal-cell carcinoma, and already genes associated with five of these syndromes have been identified — VHL, MET, FH, BHD and HRPT2. These very different genes and the biochemical pathways in which they participate raise interesting questions about the development of renal cancers and could lead to new therapeutic approaches in the near future. So, what is known about hereditary renal cancer at present?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zbar, B., Klausner, R. & Linehan, W. M. Studying cancer families to identify kidney cancer genes. Annu. Rev. Med. 54, 217–233 (2003).
Chow, W. H., Devesa, S. S., Warren, J. L. & Fraumeni, J. F. Jr. Rising incidence of renal cell cancer in the United States. JAMA 281, 1628–1631 (1999).
Kovacs, G. et al. The Heidelberg classification of renal cell tumours. J. Pathol. 183, 131–133 (1997).
Latif, F. et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 260, 1317–1320 (1993). Describes the identification and cloning of the VHL tumour-suppressor gene and intragenic mutations in members of families with VHL.
Schmidt, L. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nature Genet. 16, 68–73 (1997). First report of activating mutations in the MET proto-oncogene in inherited human cancer and identification of the causative gene for HPRC.
Tomlinson, I. P. et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nature Genet. 30, 406–410 (2002). Identification of germline inactivating mutations in FH that predispose to HLRCC with papillary type-2 renal carcinoma.
Nickerson, M. L. et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt–Hogg–Dubé syndrome. Cancer Cell 2, 157–164 (2002). Identification of germline protein-truncating mutations in a novel gene, BHD , in families with BHD syndrome leading to renal neoplasia of various histologies.
Carpten, J. D. et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nature Genet. 32, 676–680 (2002). First report of germline inactivating mutations in a novel tumour-suppressor gene, HRPT2 , in families with HPT-JT syndrome and associated renal neoplasia.
Cohen, A. J. et al. Hereditary renal-cell carcinoma associated with a chromosomal translocation. N. Engl. J. Med. 301, 592–595 (1979). First report of a family with a balanced translocation involving chromosome 3 and a predisposition to renal-cell carcinoma.
Kovacs, G., Brusa, P. & De Riese, W. Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas. Int. J. Cancer 43, 422–427 (1989).
Bodmer, D. et al. An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation. Am. J. Hum. Genet. 62, 1475–1483 (1998).
Malchoff, C. D. et al. Papillary thyroid carcinoma associated with papillary renal neoplasia: genetic linkage analysis of a distinct heritable tumor syndrome. J. Clin. Endocrinol. Metab. 85, 1758–1764 (2000).
Lendvay, T. S. & Marshall, F. F. The tuberous sclerosis complex and its highly variable manifestations. J. Urol. 169, 1635–1642 (2003).
Krymskaya, V. P. Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal. 15, 729–739 (2003).
Dome, J. S. & Coppes, M. J. Recent advances in Wilms' tumor genetics. Curr. Opin. Pediatr. 14, 5–11 (2002).
Maher, E. R. & Kaelin, W. G. Jr. von Hippel-Lindau disease. Medicine 76, 381–391 (1997).
Chen, F. et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum. Mutat. 5, 66–75 (1995).
Zbar, B. et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat. 8, 348–357 (1996).
Crossey, P. A. et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum. Genet. 93, 53–58 (1994).
Herman, J. G. et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700–9704 (1994).
Vortmeyer, A. O. et al. Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion. Oncogene 21, 1167–1170 (2002).
Lubensky, I. A. et al. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am. J. Pathol. 149, 2089–2094 (1996).
Mandriota, S. J. et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1, 459–68 (2002).
Foster, K. et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum. Mol. Genet. 3, 2169–2173 (1994).
Gnarra, J. et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature Genet. 7, 85–90 (1994). First demonstration of VHL mutation and LOH in most of sporadic clear-cell renal-cell carcinomas, which is the most common form of renal cancer.
Shuin, T. et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas. Cancer Res. 54, 2852–2855 (1994).
Kaelin, W. G. Jr. Molecular basis of the VHL hereditary cancer syndrome. Nature Rev. Cancer 2, 673–682 (2002).
Kaelin, W. G. Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J. Am. Soc. Nephrol. 14, 2703–2711 (2003).
Maxwell, P. HIF-1: an oxygen response system with special relevance to the kidney. J. Am. Soc. Nephrol. 14, 2712–2722 (2003).
Kim, W. & Kaelin, W. G. Jr. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr. Opin. Genet. Dev. 13, 55–60 (2003).
Pugh, C. W. & Ratcliffe, P. J. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin. Cancer Biol. 13, 83–89 (2003).
Maxwell, P. H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399, 271–275 (1999). Landmark publication that demonstrated an interaction between VHL and HIF proteins, and stability of HIF-α subunits in VHL-deficient cell lines.
Semenza, G. L. Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1. Annu. Rev. Cell Dev. Biol. 15, 551–578 (1999).
Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337–1340 (2001).
Stebbins, C. E., Kaelin, W. G. Jr. & Pavletich, N. P. Structure of the VHL-Elongin C-Elongin B complex: implications for VHL tumor suppressor function. Science 284, 455–461 (1999). Crystal structure of VHL protein in complex with elongins B and C that identified the frequently mutated α- and β-domains.
Pause, A. et al. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc. Natl Acad. Sci. USA 94, 2156–2161 (1997).
Hon, W. C. et al. Structural basis for the recognition of hydroxyproline in HIF-1 α by pVHL. Nature 417, 975–978 (2002).
Min, J. H. et al. Structure of an HIF-1α-pVHL complex: hydroxyproline recognition in signaling. Science 296, 1886–1889 (2002).
Ivan, M. et al. HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464–468 (2001). This paper and reference 40 demonstrated that the VHL–HIF interaction is regulated by oxygen-dependent prolyl hydroxylation.
Jaakkola, P. et al. Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292, 468–472 (2001).
Cockman, M. E. et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275, 25733–25741 (2000).
Ohh, M. et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein. Nature Cell Biol. 2, 423–427 (2000).
Lando, D., Peet, D. J., Whelan, D. A., Gorman, J. J. & Whitelaw, M. L. Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch. Science 295, 858–861 (2002).
Mahon, P. C., Hirota, K. & Semenza, G. FIH-1: a novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675–2686 (2001).
Iliopoulos, O., Kibel, A., Gray, S. & Kaelin, W. G. Jr. Tumor suppression by the human von Hippel-Lindau gene product. Nature Med. 1, 822–826 (1995). This was the first report to identify the VHL gene product in cells and the first to show that restoration of wild-type VHL function in VHL−/− renal carcinoma cells suppressed the formation of tumours in nude mice.
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M. & Kaelin, W. G. Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1, 237–246 (2002). The creation of a stable HIF mutant prevents tumour suppression by VHL in a nude mouse model, implicating the VHL–HIF interaction as critical to the growth of renal cancer cells.
Kondo, K., Kim, W. Y., Lechpammer, M. & Kaelin, W. G., Jr. Inhibition of HIF2α is sufficient to suppress pVHL-defective tumor growth. PLOS Biol. 1, 439–444 (2003).
Maranchie, J. K. et al. The contribution of VHL substrate binding and HIF1-α to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1, 247–255 (2002). VHL substrate binding at the HIF recognition domain of VHL protein was shown to be essential to the tumour-suppressor function of VHL, but artificially increasing HIF levels alone was not sufficient for tumorigenesis.
Gnarra, J. R. et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA 93, 10589–10594 (1996).
Levy, A. P., Levy, N. S. & Goldberg, M. A. Hypoxia-inducible protein binding to vascular endothelial growth factor mRNA and its modulation by the von Hippel-Lindau protein. J. Biol. Chem. 271, 25492–25497 (1996).
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G. Jr & Goldberg, M. A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl Acad. Sci. USA 93, 10595–10599 (1996).
Siemeister, G. et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res. 56, 2299–2301 (1996).
Knebelmann, B., Ananth, S., Cohen, H. T. & Sukhatme, V. P. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res. 58, 226–231 (1998).
de Paulsen, N. et al. Role of transforming growth factor-α in von Hippel—Lindau (VHL)−/− clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc. Natl Acad. Sci. USA 98, 1387–1392 (2001).
Ohh, M. et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol. Cell 1, 959–968 (1998).
Chen, F. et al. Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene. Cancer Res. 55, 4804–4807 (1995).
Pause, A., Lee, S., Lonergan, K. M. & Klausner, R. D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc. Natl Acad. Sci. USA 95, 993–998 (1998).
Davidowitz, E. J., Schoenfeld, A. R. & Burk, R. D. VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling. Mol. Cell. Biol. 21, 865–874 (2001).
Bindra, R. S., Vasselli, J. R., Stearman, R., Linehan, W. M. & Klausner, R. D. VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells. Cancer Res. 62, 3014–3019 (2002).
Baba, M. et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22, 2728–2738 (2003).
Staller, P. et al. Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor pVHL. Nature 425, 307–311 (2003).
Zbar, B. et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum. Mutat., 8, 348–357 (1996).
Friedrich, C. A. Genotype-phenotype correlation in von Hippel-Lindau syndrome. Hum. Mol. Genet. 10, 763–767 (2001).
Clifford, S. C. et al. Contrasting effects on HIF-1α regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum. Mol. Genet. 10, 1029–1038 (2001).
Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P. & Krek, W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nature Cell Biol. 5, 64–70 (2003).
Hoffman, M. A. et al. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hum. Mol. Gen. 10, 1019–1027 (2001).
Feldman, D. E., Spiess, C., Howard, D. E. & Frydman, J. Tumorigenic mutations in VHL disrupt folding in vivo by interfering with chaperonin binding. Mol. Cell 12, 1213–1224 (2003).
Maranchie, J. K. et al. Solid renal tumor severity in von Hippel Lindau disease is related to germline deletion length and location. Hum. Mutat. 23, 40–46 (2004).
Gnarra, J. R. et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc. Natl Acad. Sci. USA 94, 9102–9107 (1997).
Haase, V. H., Glickman, J. N., Socolovsky, M. & Jaenisch, R. Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc. Natl Acad. Sci. USA 98, 1583–1588 (2001).
Ma, W. et al. Hepatic vascular tumors, angiectasis in multiple organs, and impaired spermatogenesis in mice with conditional inactivation of the VHL gene. Cancer Res. 63, 5320–5328 (2003).
Zbar, B. et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J. Urol. 153, 907–912 (1995).
Schmidt, L. et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res. 58, 1719–1722 (1998).
Schmidt, L. et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18, 2343–2350 (1999).
Olivero, M. et al. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family. Int. J. Cancer 82, 640–643 (1999).
Bottarro, D. P. et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 251, 802–804 (1991). A molecule upregulated after treatment of target cells in vitro with HGF was found to be identical to the c-MET proto-oncogene product, now known as the HGF transmembrane tyrosine kinase receptor.
Bardelli, A., Pugliese, L. & Comoglio, P. M. 'Invasive growth' signalling by the Met/HGF receptor. The hereditary renal carcinoma connection. Biochim. Biophys. Acta. 1333, M41–M51 (1997).
Comoglio, P. M. Pathway specificity for Met signaling. Nature Cell Biol. 3, E161–E162 (2001).
Birchmeier, C., Birchmeier, W., Gherardi, E. & Vande Woude, G. F. Met, metastasis, motility and more. Nature Rev. Mol. Cell Biol. 4, 915–925 (2003).
Trusolino, L. & Comoglio, P. M. Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nature Rev. Cancer 2, 289–300 (2002).
Jeffers, M. et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl Acad. Sci. USA 94, 11445–11450 (1997).
Hofstra, R. M. et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367, 375–376 (1994).
Nagata, H. et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl Acad. Sci. USA 92, 10560–10564 (1995).
Shu, H. K., Pelley, R. J. & Kung, H. J. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential. Proc. Natl Acad. Sci. USA 87, 9103–9107 (1990).
Miller, M. et al. Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies. Proteins 44, 32–43 (2001).
Michieli, P. et al. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists. Oncogene 18, 5221–5231 (1999).
Chiara, F., Michieli, P., Pugliese, L. & Comoglio, P. M. Mutations in the met oncogene unveil a 'dual switch' mechanism controlling tyrosine kinase activity. J. Biol. Chem. 278, 29352–29358 (2003).
Zhuang, Z. et al. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nature Genet. 20, 66–69 (1998).
Fischer, J. et al. Duplication and overexpression of the mutant allele of the MET proto-oncogene in multiple hereditary papillary renal cell tumours. Oncogene 17, 733–739 (1998).
Schmidt, C. et al. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373, 699–702 (1995).
Uehara, Y. et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor. Nature 373, 702–705 (1995).
Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A. & Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376, 768–771 (1995).
Jeffers, M. et al. The mutationally activated Met receptor mediates motility and metastasis. Proc. Natl Acad. Sci. USA 95, 14417–14422 (1998).
Liang, T. J., Reid, A. E., Xavier, R., Cardiff, R. D. & Wang, T. C. Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors. J. Clin. Invest. 97, 2872–2877 (1996).
Launonen, V. et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc. Natl Acad. Sci. USA 98, 3387–3392 (2001).
Kiuru, M. et al. Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology. Am. J. Pathol. 159, 825–829 (2001).
Delahunt, B. et al. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum. Pathol. 32, 590–595 (2001).
Jiang, F. et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am. J. Pathol. 153, 1467–1473 (1998).
Toro, J. et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am. J. Hum. Genet. 73, 95–106 (2003).
Alam, N. A. et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum. Mol. Genet. 12, 1241–1252 (2003).
Alam, N. A. et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42. 3-q43. Am. J. Hum. Genet. 68, 1264–1269 (2001).
Kiuru, M. et al. Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res. 62, 4554–4557 (2002).
Bevan, S. et al. Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer. Prostate Cancer Prostatic Dis. 6, 12–14 (2003).
Barker, K. T. et al. Low frequency of somatic mutations in the FH/multiple cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and uterine leiomyomas. Br. J. Cancer 87, 446–448 (2002).
Coughlin, E. M. et al. Molecular analysis and prenatal diagnosis of human fumarase deficiency. Mol. Genet. Metab. 63, 254–262 (1998).
Eng, C., Kiuru, M., Fernandez, M. J. & Aaltonen, L. A. A role for mitochondrial enzymes in inherited neoplasia and beyond. Nature Rev. Cancer 3, 193–202 (2003).
Vanharanta, S. et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am. J. Hum. Genet. 74, 153–159 (2004).
Birt, A. R., Hogg, G. R. & Dubé, W. J. Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons. Arch. Dermatol. 113, 1674–1677 (1977).
Weirich, G. et al. Familial renal oncocytoma: clinicopathological study of 5 families. J. Urol. 160, 335–340 (1998).
Toro, J. et al. Birt–Hogg–Dubé syndrome: a novel marker of kidney neoplasia. Arch. Dermatol. 135, 1195–1202 (1999).
Zbar, B. et al. Risk of renal and colonic neoplasms and spontaneous pneumothorax in the Birt–Hogg–Dubé syndrome. Cancer Epidemiol. Biomarkers Prev. 11, 393–400 (2002). An attempt to define BHD as a cancer-predisposition syndrome from its humble origins as a 'simple' genodermatosis.
Khoo, S. K. et al. Clinical and genetic studies of Birt–Hogg–Dubé syndrome. J. Med. Genet. 39, 906–912 (2002).
Pavlovich, C. P. et al. Renal tumors in the Birt–Hogg–Dubé syndrome. Am. J. Surg. Pathol. 26, 1542–1552 (2002).
Tickoo, S. K. et al. Renal oncocytosis: a morphologic study of fourteen cases. Am. J. Surg. Pathol. 23, 1094–1101 (1999).
Schmidt, L. S. et al. Birt–Hogg–Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11. 2. Am. J. Hum. Genet. 69, 876–882 (2001).
Khoo, S. K. et al. Birt–Hogg–Dubé syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11. 2. Oncogene 20, 5239–5242 (2001).
Streisinger, G. et al. Frameshift mutations and the genetic code. Cold Spring Harbor Symp. Quant. Biol. 31, 77–86 (1966).
Okimoto, K. et al. A novel 'Nihon' rat model of a Mendelian dominantly inherited renal cell carcinoma. Jpn J. Cancer Res. 91, 1096–1099 (2000). A spontaneous and now established rat model of renal cancer similar to human BHD that may be a valuable research tool. Also see references 119 and 120.
Hino, O., Okimoto, K., Kouchi, M. & Sakurai, J. A novel renal carcinoma predisposing gene of the Nihon rat maps on chromosome 10. Jpn J. Cancer Res. 92, 1147–1149 (2001).
Okimoto, K. et al. A germ-line insertion in the Birt–Hogg–Dubé (BHD) gene gives rise to the Nihon rat model of inherited renal cancer. Proc. Natl Acad. Sci. USA 101, 2023–2027 (2004).
Lium, B. & Moe, L. Hereditary multifocal renal cystadenocarcinomas and nodular dermatofibrosis in the German shepherd dog: macroscopic and histopathologic changes. Vet. Pathol. 22, 447–455 (1985).
Jonasdottir, T. J. et al. Genetic mapping of a naturally occurring hereditary renal cancer syndrome in dogs. Proc. Natl Acad. Sci. USA 97, 4132–4137 (2000).
Lingaas, F. et al. A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis in the German Shepherd dog. Hum. Mol. Genet. 12, 3043–3053 (2003). The first natural large animal model for renal-cell carcinoma.
Khoo, S. K. et al. Inactivation of BHD in sporadic renal tumors. Cancer Res. 63, 4583–4587 (2003).
da Silva, N. F. et al. Analysis of the Birt–Hogg–Dubé (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J. Med. Genet. 40, 820–824 (2003).
Pavlovich, C. P. et al. Genetic analysis of renal cell carcinomas in Birt–Hogg–Dubé (BHD) syndrome. Proc. Am. Assoc. Cancer Res. 43, 632 (2002).
Shin, J. H. et al. Mutations of the Birt–Hogg–Dubé (BHD) gene in sporadic colorectal carcinomas and colorectal carcinoma cell lines with microsatellite instability. J. Med. Genet. 40, 364–367 (2003).
Kahnoski, K. et al. Alterations of the Birt–Hogg–Dubé gene (BHD) in sporadic colorectal tumours. J. Med. Genet. 40, 511–515 (2003).
Jackson, C. E. et al. Hereditary hyperparathyroidism and multiple ossifying jaw fibromas: a clinically and genetically distinct syndrome. Surgery 108, 1006–1012 (1990).
Szabo, J. et al. Hereditary hyperparathyroidism-jaw tumor syndrome: the endocrine tumor gene HRPT2 maps to chromosome 1q21-q31. Am. J. Hum. Genet. 56, 944–950 (1995).
Teh, B. T. et al. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas. J. Clin. Endocrinol. Metab. 81, 4204–4211 (1996).
Haven, C. J. et al. A genotypic and histopathological study of a large Dutch kindred with hyperparathyroidism-jaw tumor syndrome. J. Clin. Endocrinol. Metab. 85, 1449–1454 (2000).
Shattuck, T. M. et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349, 1722–1729 (2003).
Howell, V. M. et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Med. Genet. 40, 657–663 (2003).
Bodmer, D. et al. Understanding familial and non-familial renal cell cancer. Human Mol. Genet. 11, 2489–2498 (2002).
Ohta, M. et al. The FHIT gene, spanning the chromosome 3p14. 2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84, 587–597 (1996).
Ong, S. T. et al. Precise localization of the FHIT gene to the common fragile site at 3p14. 2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines. Genes Chromosom. Cancer 20, 16–23 (1997).
Siprashvili, Z. et al. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl Acad. Sci. USA 94, 13771–13776 (1997).
Gemmill, R. M. et al. The hereditary renal cell carcinoma 3;8 translocation fuses FHIT to a patched-related gene, TRC8. Proc. Natl Acad. Sci. USA 95, 9572–9577 (1998).
Gemmill, R. M. et al. The TRC8 hereditary kidney cancer gene suppresses growth and functions with VHL in a common pathway. Oncogene 21, 3507–3516 (2002).
Druck, T. et al. The DIRC1 gene at chromosome 2q33 spans a familial RCC-associated t(2;3)(q33;q21) chromosome translocation. J. Hum. Genet. 46, 583–589 (2001).
Bodmer, D. et al. Disruption of a novel MFS transporter gene, DIRC2, by a familial renal cell carcinoma-associated t(2;3)(q35;q21). Hum. Mol. Genet. 11, 641–649 (2002).
Bodmer, D., Schepens, M., Eleveld, M. J., Schoenmakers, E. F. & Geurts van Kessel, A. Disruption of a novel gene, DIRC3, and expression of DIRC3-HSPBAP1 fusion transcripts in a case of familial renal cell cancer and t(2;3)(q35;q21). Genes Chromosom. Cancer 38, 107–116 (2003).
Chen, J. et al. The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. Cancer Cell 4, 405–413 (2003).
Schmidt, L. et al. Mechanism of tumorigenesis of renal carcinomas associated with the constitutional chromosome 3;8 translocation. Cancer J. Sci. Am. 1, 191–194 (1995).
Woodward, E. R., Clifford, S. C., Astuti, D., Affara, N. A. & Maher, E. R. Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes. J. Med. Genet. 37, 348–353 (2000).
Teh, B. T. et al. Familial non-VHL non-papillary clear cell renal cancer. Lancet 349, 848–849 (1997).
Gudbjartsson, T. et al. A population-based familial aggregation analysis indicates genetic contribution in a majority of renal cell carcinomas. Int. J. Cancer 100, 476–479 (2002). Shows that the future of gene discovery for RCC could rely on the discovery of predispositions that are more subtle than those found so far, which have been autosomal dominant syndromes following classic Mendelian inheritance.
Gago-Dominguez, M., Yuan, J. M., Castelao, J. E., Ross, R. K. & Yu, M. C. Family history and risk of renal cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 10, 1001–1004 (2001).
Choyke, P. L. Imaging of hereditary renal cancer. Radiol. Clin. North Am. 41, 1037–1051 (2003).
Lonser, R. R. et al. von Hippel-Lindau disease. Lancet 361, 2059–2067 (2003).
Stolle, C. et al. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum. Mutat. 12, 417–423 (1998).
Herring, J. C. et al. Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J. Urol. 165, 777–781 (2001). Along with reference 156, a demonstration that nephron-sparing approaches are appropriate for patients with syndromes placing them at continued risk of renal neoplasia.
Pavlovich, C. P. et al. Percutaneous radiofrequency ablation of small renal tumors: initial results. J. Urol. 167, 10–15 (2002).
Shingleton, W. B. & Sewell, P. E. Jr. Percutaneous renal cryoablation of renal tumors in patients with von Hippel-Lindau disease. J. Urol. 167, 1268–1270 (2002).
Steinbach, F. et al. Treatment of renal cell carcinoma in von Hippel-Lindau disease: a multicenter study. J. Urol. 153, 1812–1816 (1995).
Grady, W. M. Genetic and epigenetic alterations in colon cancer. Annu. Rev. Genomics Hum. Genet. 3, 101–128 (2002).
Pennacchietti, S. et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347–361 (2003).
Koochekpour, S. et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol. Cell Biol. 19, 5902–5912 (1999).
Amato, R. J. Thalidomide therapy for renal cell carcinoma. Crit. Rev. Oncol. Hematol. 46, S59–S65 (2003).
Lara, P. N. Jr et al. SU5416 plus interferon α in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin. Cancer Res. 9, 4772–4781 (2003).
Yang, J. C. et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349, 427–434 (2003).
Sattler, M. et al. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 63, 5462–5469 (2003).
Webb, C. P. et al. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60, 342–349 (2000).
Alizadeh, A. A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503–511 (2000).
Bittner, M. et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406, 536–540 (2000).
Higgins, J. P. et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am. J. Pathol. 162, 925–932 (2003).
Takahashi, M. et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl Acad. Sci. USA 98, 9754–9759 (2001).
Vasselli, J. R. et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc. Natl Acad. Sci. USA 100, 6958–6963 (2003).
Acknowledgements
This publication has been funded in part with Federal funds from the National Cancer Institute, National Institutes of Health. The content of this publication does not reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the United States Government.
Correction: The DOI number given for this article in the May 2004 print issue of Nature Reviews Cancer was wrong. The correct DOI number is: doi:10.1038/nrc1364.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
DATABASES
Cancer.gov
Locuslink
OMIM
familial papillary thyroid carcinoma
hereditary leiomyomatosis and renal-cell cancer
hereditary papillary renal carcinoma
hyperparathyroidism-jaw tumour syndrome
multiple cutaneous and uterine leiomyomatosis
FURTHER INFORMATION
Glossary
- KREBS CYCLE
-
Also known as tricarboxylic-acid cycle. A series of enzymatic reactions that break down pyruvate to carbon dioxide and hydrogen atoms, which are in turn transferred to specific coenzymes for the oxidative generation of ATP in the mitochondria.
- GENODERMATOSIS
-
An inherited syndrome involving a dermatological phenotype and possibly other phenotypes.
- ONCOCYTOMA
-
Large tumour cells with poorly defined borders, granular eosinophilic cytoplasm and large, basophilic nuclei.
- PENETRANCE
-
The frequency with which individuals who carry a given gene mutation will show the manifestations associated with the gene syndrome. If penetrance of a disease allele is 100%, then all individuals carrying that allele will express the associated phenotype.
- LOSS OF HETEROZYGOSITY
-
(LOH). In cells that carry a mutated allele of a tumour-suppressor gene, the gene becomes fully inactivated when the cell loses a large part of the chromosome carrying the wild-type allele. Regions with a high frequency of LOH are believed to harbour tumour-suppressor genes.
- HYPERMETHYLATION
-
Methylation of a CpG island in a promoter of a gene usually prevents expression of the gene and can be used to regulate gene expression in a tissue-specific manner. Tumour-suppressor genes might be inactivated by mutation or hypermethylation of promoter regions.
- KNUDSON TWO-HIT HYPOTHESIS
-
In 1971, Alfred Knudson proposed that two successive genetic 'hits' are required to turn a normal cell into a tumour cell and that, in familial cancers, one 'hit' was inherited.
- PHEOCHROMOCYTOMA
-
A neuroendocrine tumour that typically arises in the adrenal medulla. These tumours can be benign or malignant. Symptoms often relate to the ability of these tumours to secrete catecholamines.
- CRE/LOX RECOMBINATION
-
A method in which the Cre recombinase enzyme catalyses recombination between loxP sequences. If the loxP sequences are arranged as a direct repeat, recombination will delete the DNA between the sites.
- EPITHELIAL–MESENCHYMAL TRANSITION
-
Conversion from an epithelial to a mesenchymal phenotype, which is a normal component of embryonic development. In carcinomas, this transformation results in altered cell morphology, the expression of mesenchymal proteins and increased invasiveness.
- MOSAICISM
-
Postzygotic mutations resulting in some, but not all, of a patient's tissues being affected by gene mutation. Patients with mosaicism represent de novo cases of a disease within the family. The patient might be asymptomatic or have less severe disease than offspring and might test negative for a germline mutation, making them difficult to diagnose.
- NONSENSE MUTATION
-
A sequence alteration in the DNA that changes a codon specific for one amino acid to a chain termination codon, that is, TAA, TAG or TGA. Termination codons produce premature truncated proteins that are likely to abolish protein function.
- CUTANEOUS LEIOMYOMAS
-
Benign smooth-muscle tumours of the skin presenting as firm, skin-coloured papules and nodules.
- UTERINE LEIOMYOMAS
-
Also known as a 'fibroids', benign smooth-muscle tumours of the uterus, the most common gynaecological tumours in women of reproductive age. Fibroids can interfere with child-bearing.
- FUMARASE DEFICIENCY
-
An autosomal-recessive disorder in which biallelic FH mutations cause gross developmental delay and death in the first decade.
- FIBROFOLLICULOMAS
-
Benign hamartomas of the hair follicle, characterized by anastomozing (branching) strands of proliferating epithelial cells extending from a central hair follicle encapsulated by loose, mucin-rich connective-tissue stroma.
- SPONTANEOUS PNEUMOTHORAX
-
A sudden rupture of lung tissue, resulting in air escaping from the lung into the pleural cavity.
- CHROMOPHOBE RCC
-
Tumour with well-defined cell borders, fluffy eosinophillic cytoplasm, pyknotic nuclei and perinuclear halos.
- ONCOCYTIC HYBRID TUMOUR
-
Hybrid tumours contain zones classic for more than one type of tumour histology. Oncocytic hybrid tumours contain areas with cells histologically consistent with oncocytoma, areas consistent with chromophobe RCC and mixed areas.
- SYNTENY
-
In this context, this term is used to refer to gene loci in different organisms that are located on a chromosomal region of common evolutionary ancestry.
- MICROSATELLITE INSTABILITY
-
Describes diploid tumours in which genetic instability is due to a high mutation rate, primarily in short nucleotide repeats. Cancers with the microsatellite instability phenotype are associated with defects in DNA mismatch-repair genes.
- HAMARTOMAS
-
Tumours comprising cells of more than one histological type.
- ODDS RATIO
-
The odds ratio is a way of comparing whether the probability of a certain event is the same for two groups, and is calculated using a 2 × 2 table. An odds ratio of one implies that an event is equally likely in both groups. An odds ratio greater than one implies that an event is more likely in the first group. An odds ratio less than one implies that the event is less likely in the first group.
Rights and permissions
About this article
Cite this article
Pavlovich, C., Schmidt, L. Searching for the hereditary causes of renal-cell carcinoma. Nat Rev Cancer 4, 381–393 (2004). https://doi.org/10.1038/nrc1364
Issue Date:
DOI: https://doi.org/10.1038/nrc1364
This article is cited by
-
Renal Cell Carcinoma: Molecular Aspects
Indian Journal of Clinical Biochemistry (2018)
-
The potential of organoids in urological cancer research
Nature Reviews Urology (2017)
-
Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
Current Oncology Reports (2017)
-
Potential role of gene-environment interactions in ion transport mechanisms in the etiology of renal cell cancer
Scientific Reports (2016)
-
CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer
Oncogene (2016)